A ZAG-S&W Team represented Cellect Biotechnology Ltd. in its initial public offering in the United States of 1,292,308 American Depository Shares (ADSs) and warrants to purchase up to 969,231 ADSs.
The gross proceeds to Cellect from this offering are $8.4 million.
July, 2016
Attorneys Oded Har-Even, Shy Baranov, Rob Condon, David Huberman and Ron Ben-Bassat, represented Renshaw & Rodman.
June, 2016
Attorneys Oded Har-Even, Howard Berkenblit, Rob Condon and Ron Ben Bassat represented the company.
July, 2016
Attorneys Oded Har-Even, Rob Condon, Hila Nahum, Jene Schlack and Ron Ben-Bassat, represented Gunner & Joseph who served as an underwriter in the offering.
July, 2016
The team includud Oded Har-Even, Robert Condon, Ron Ben Bassat and Leigh Sapir-Kashi. Roth Capital Partners acted as the lead placement agent and Maxim Group LLC acted as the co-placement agent for this transaction.
September, 2016
The ZAG-S&W team included Oded Har-Even, Howard Berkenblit, Rob Condon, Shy Baranov, David Huberman, Ron Ben-Bassat and Hila Nahum.
September, 2016
Attornyes Oded Har-Even, Shy Baranov, Rob Condon, Ron Ben-Bassat and Hila Nahum represented Aegis Capital Corp. as Lead Placement Agent in an approximately $5 million concurrent registered direct and private placement offering of ordinary shares, debentures and warrants by Rosetta Genomics, which develops and commercializes a full range of microRNA-based and other molecular diagnostics.
December, 2016
Attornyes Oded Har-Even, Shy Baranov, Rob Condon, Ron Ben-Bassat and Hila Nahum represented Aegis Capital Corp. as Lead Placement Agent in an approximately $12.4 million private placement offering of preferred shares By Rennova Health Inc.
December, 2016
Attornyes Oded Har-Even, Ron Ben-Bassat and Robert Condon represented DarioHealth Corp. in the private placement.
The deal was led by OurCrowd Qure, a dedicated digital health fund.
January, 2017
Advs. Oded Har-Even, Rob Condon and Ron Ben-Bassat from the American Capital Markets departmemt at the firm represented the company in a private placement on Nasdaq
Globes, 15.1.2017